CDK4 Recombinant Antibody

Flow cytometric analysis of MCF7 cells with Cdk4 (6A4) Monoclonal Antibody (bsm-52651R) at 1:50 dilution (red) compared with an unlabeled control (cells without incubation with primary antibody; black).

$Hela cells Probed with Cdk4 (6A4) Monoclonal Antibody (bsm-52651R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Hela cells Probed with Cdk4 (6A4) Monoclonal Antibody (bsm-52651R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

$IF(ICC) staining with Cdk4 (6A4) Monoclonal Antibody (bsm-52651R) at 1:300 in HeLa cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with Cdk4 (6A4) Monoclonal Antibody (bsm-52651R) at 1:300 in HeLa cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$IF(ICC) staining with Cdk4 (6A4) Monoclonal Antibody (bsm-52651R) at 1:300 in MCF-7 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with Cdk4 (6A4) Monoclonal Antibody (bsm-52651R) at 1:300 in MCF-7 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$IF(ICC) staining with Cdk4 (6A4) Monoclonal Antibody (bsm-52651R) at 1:300 in NIH\/3T3 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.$

IF(ICC) staining with Cdk4 (6A4) Monoclonal Antibody (bsm-52651R) at 1:300 in NIH\/3T3 cells (green). The nuclear counterstain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilized with 0.25% Triton X100\/PBS.

$Paraformaldehyde-fixed and paraffin-embedded Human breast carcinoma tissue incubated with Cdk4 (6A4) Monoclonal Antibody (bsm-52651R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human breast carcinoma tissue incubated with Cdk4 (6A4) Monoclonal Antibody (bsm-52651R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

Applications

WB
FCM
IHC-P
IF(ICC)
IHC

Reactivity

Human
Mouse

Overview
Catalog #	bsm-52651R
Product Name	CDK4 Recombinant Antibody
Applications	WB FCM IHC-P IF(ICC) IHC
Reactivity	Human, Mouse
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	C terminal Human Cdk4
Clonality	Monoclonal
Clone #	6A4
Isotype	IgG
Concentration	Lot Dependent
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Store at -20°C for 12 months.
Target
Gene ID	1019
Swiss Prot	P11802
Synonyms	Cyclin-dependent kinase 4, Cell division protein kinase 4, PSK-J3, CDK4
Background	Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also phosphorylates SMAD3 in a cell-cycle-dependent manner and represses its transcriptional activity. Component of the ternary complex, cyclin D/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex.
Application Dilution
WB	1:300-5000
FCM	1:20-100
IHC-P	1:200-400
IF(ICC)	1:50-200
IHC